
NOVELTY study animation
Watch our short animation to learn more about the NOVELTY study.
Read MoreThe NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study of patients with a diagnosis or suspected diagnosis of asthma and/or COPD. NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, providing real-world evidence to advance the development of precision medicine to deliver the right treatment to the right patient at the right time. The NOVELTY study is sponsored by AstraZeneca.
Six NOVELTY ePosters were presented at the virtual ERS Congress 2020, and the related abstracts have now been published online.
Read MoreWe are pleased to announce that ‘Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design’ has been published.
Read MoreRead summaries of publications and presentations relating to the NOVELTY study and access useful NOVELTY resources.
Read MoreYou are now leaving: http://aznoveltyproject.com/
By following this link you will be leaving the NOVELTY study website.
Please note that AstraZeneca does not take responsibility for the content displayed on other websites.